Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Natural Remedies

Real Time Snapshot Of The Learning Process
To learn from experience, it is essential to know whether a past action was associated with a desired outcome. Now, scientists have demonstrated how this information can be coded by a single cell. The research, published in the July 30th issue of the journal Neuron, provides strong support for a neural mechanism that allows reward signals to be combined over time to drive successful learning.
generic viagra online
Agent Provides Treatment Option For Women With Hot Flashes
A pill used for nerve pain offers women relief from hot flashes, Mayo Clinic researchers report at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO).
News of the day
AccuVein Launches First Portable, Non-Contact Vein Illumination Device
AccuVein LLC announced the launch of AccuVein AV300, the world"s first hand-held, non-contact vein illumination device that helps healthcare professionals locate hard-to-find veins. IV starts and blood draws (venipuncture) can be a of patient anxiety and discomfort, and accessing veins in difficult patients can take up to 10 minutes and require multiple needle sticks. Venipuncture is the most common invasive medical procedure with an estimated 2.7 million procedures conducted every day in the United States alone. The AV300 can help reduce the need for multiple needle sticks, with the goal of improving patient care and the time to access veins.
Sexual Health

Accumetrics, Inc. Announces 1000th Patient Enrolled In GRAVITAS Trial

Accumetrics, Inc. announces that it has enrolled its 1,000th patient into its landmark clinical trial, GRAVITAS (Gauging Responsiveness with A VerifyNow(R) Assay Impact on Thrombosis And Safety). The trial is specifically designed to demonstrate the value of providing clinicians with actionable information for patients who are poor responders to clopidogrel (Plavix(R)). The multi-center, placebo controlled trial will determine whether tailored antiplatelet therapy for poor responders, identified based on the results of the company"s VerifyNow P2Y12 Test, reduces major cardiovascular adverse events (e.g., heart attack, stent thrombosis) following percutaneous coronary intervention (PCI). Currently the trial is being conducted at more than 70 sites in the U.S. and Canada, with a total enrollment goal of approximately 2,800 patients. "This is a very significant milestone for Accumetrics as it brings us ever-closer to our goal of demonstrating the value of the VerifyNow System. By identifying and adjusting therapy for patients that are not responding adequately to standard doses of clopidogrel, GRAVITAS will be the largest multi-center clinical trial that links testing with personalized medicine and improved outcomes. We believe that the VerifyNow System will be seen as an integral tool in ensuring that patients receive not only the most appropriate antiplatelet therapy, but also the adequate dose," said Jeff Dahlen, Ph.D, Vice President, Clinical and Regulatory Affairs of Accumetrics, Inc. "We are very proud to reach this milestone, and look forward to completing enrollment soon, and sharing the results." About GRAVITAS The concept of variability in response to antiplatelet therapy has been well established. The question of whether poor response to antiplatelet therapy, as measured by a laboratory test, leads to poor outcomes is also being demonstrated with increased frequency. However, Accumetrics recognizes the need for a study specifically designed to demonstrate the value of providing clinicians with actionable information to improve outcomes for those patients who are poor responders to antiplatelet therapy. As a result, the GRAVITAS study is the first multi-center, placebo-controlled study to determine whether tailored antiplatelet therapy based on the results of the company"s VerifyNow System reduces major cardiovascular adverse events post-PCI. Accumetrics, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009